Free Trial

Buy Moderna For Its Ceiling and Pfizer For its Floor

Buy Moderna For Its Ceiling and Pfizer For its Floor

The United States is rapidly approaching nine months of having the Pfizer (NYSE:PFEand Moderna (NASDAQ:MRNACovid-19 vaccines approved under an emergency use authorization (EUA). While both companies continue to generate significant revenue from the vaccines, MRNA stock has significantly outperformed PFE stock over the past 12 months as well as in 2021. 

Both companies are expected to post strong numbers this earnings season. Pfizer reports on July 28 and Moderna will report on August 5. But are investors too late? That’s what I’ll be looking at in this article.  

Unless you’ve been deliberately tuning out the news, you’re aware of the Delta variant of the novel coronavirus. Each variant of the virus is being assigned a letter of the Greek alphabet, so the Delta variant is the fourth variant to be identified. 

It appears that the Delta variant is hitting the unvaccinated population harder. And that is putting the Covid-19 vaccines back on the front burner for investors. In particular, the conversation is about Pfizer and Moderna, the developers of the mRNA vaccines.  

These vaccines are the first of their kind. Without delving too far into the science, a key distinction of the mRNA vaccines is that recipients to not receive any part of a live virus. That distinction, among others, is either a positive or negative for individuals contemplating whether to get the vaccine.  

Will the Revenue Keep Coming In? 

However, the question that investors need to ask is will the variant be additive to company revenue. According to Forbes, the answer is a resounding Yes as it relates to Pfizer. The company is expected to have annual sales in 2021 of $35 billion. And of the company’s $14.6 billion in sales in the first quarter, $3.5 billion came from sales of the Covid-19 vaccine. That number is expected to be significantly higher when the company reports second-quarter earnings.  

A similar story is playing out with Moderna. The company is projected to deliver $4.27 billion in revenue when it reports earnings. Since the company’s only product that is available for commercial use is its Covid-19 vaccine, its reasonable that all that revenue is vaccine related.  

Is the Delta Variant a Catalyst? 

This is harder to say with certainty. The variant is putting the vaccine rollout under the microscope, but it hasn’t changed the supply-demand dynamic. In June 2021, Pfizer received an EUA that allows its vaccine to be given to anyone above the age of 12. Moderna is applying for an EUA to administer is a vaccine to children 12-18. The companies are making supply agreements with foreign countries to make the vaccines available under EUAs. 

And, while no consensus has been reached, it appears increasingly likely that booster shots may be required at some unspecified date. This should keep revenue flowing for both companies.  

Still, none of these are directly related to the Delta variant. So don’t buy on the emotion that is being stirred up.  

What Type of Investor Are You? 

Normally I like to fall on one name of the other. In this case, I believe both stocks are good buys but it depends on what’s important to you. Moderna is looking to make its mRNA technology available over a wide spectrum of vaccines. The success of the company’s Covid-19 vaccine should make it easier to get their existing candidates through clinical trials. 

But that will still take some time, and there is no guarantee of success. However, the company should be well funded as it goes through the process.  

On the other hand, Pfizer has a prolific menu of products that are in market. But that’s also a reason why PFE stock has only delivered 20% growth in the last five years. It’s a mature player in the field. It even pays a modest dividend. 

My advice is simple. Buy Moderna for its ceiling and Pfizer for its floor.  

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Chris Markoch
About The Editor

Chris Markoch

Editor & Contributing Author

Retirement, Individual Investing

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
4.7398 of 5 stars
4.74 / 5 stars
Moderna (MRNA)
3.842 of 5 stars
3.84 / 5 stars
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

4 Best Tech Stocks to Own in 2024

4 Best Tech Stocks to Own in 2024

In this video, we explore the recent selloff and rotation of investments from NVDA to other Magnificent 7 stocks. Our analysts highlight four standout stocks—Amazon, Apple, Meta, and Alphabet.

Related Videos

NVIDIA Tops Microsoft and Apple for Most Valuable Company
3 Strong Buy Stocks for a Summer Surge
Buy or Bail? Stock Upgrades and Downgrades

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines